These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 23147500)
1. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. Benet LZ J Pharm Sci; 2013 Jan; 102(1):34-42. PubMed ID: 23147500 [TBL] [Abstract][Full Text] [Related]
2. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies. Cristofoletti R; Chiann C; Dressman JB; Storpirtis S J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377 [TBL] [Abstract][Full Text] [Related]
3. Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts. Camenisch GP Pharm Res; 2016 Nov; 33(11):2583-93. PubMed ID: 27439505 [TBL] [Abstract][Full Text] [Related]
4. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626 [TBL] [Abstract][Full Text] [Related]
5. BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs. Hosey CM; Chan R; Benet LZ AAPS J; 2016 Jan; 18(1):251-60. PubMed ID: 26589308 [TBL] [Abstract][Full Text] [Related]
6. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482 [TBL] [Abstract][Full Text] [Related]
7. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Wu CY; Benet LZ Pharm Res; 2005 Jan; 22(1):11-23. PubMed ID: 15771225 [TBL] [Abstract][Full Text] [Related]
8. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines. Charalabidis A; Sfouni M; Bergström C; Macheras P Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154 [TBL] [Abstract][Full Text] [Related]
9. State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References. Bocci G; Oprea TI; Benet LZ AAPS J; 2022 Feb; 24(2):37. PubMed ID: 35199251 [TBL] [Abstract][Full Text] [Related]
10. Is the full potential of the biopharmaceutics classification system reached? Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971 [TBL] [Abstract][Full Text] [Related]
11. Solubility-Permeability Interplay in Facilitating the Prediction of Drug Disposition Routes, Extent of Absorption, Food Effects, Brain Penetration and Drug Induced Liver Injury Potential. Benet LZ J Pharm Sci; 2023 Sep; 112(9):2326-2331. PubMed ID: 37429358 [TBL] [Abstract][Full Text] [Related]
13. Prediction of Biopharmaceutical Drug Disposition Classification System (BDDCS) by Structural Parameters. Golfar Y; Shayanfar A J Pharm Pharm Sci; 2019; 22(1):247-269. PubMed ID: 31287788 [TBL] [Abstract][Full Text] [Related]
14. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted. Benet LZ; Larregieu CA Clin Pharmacol Ther; 2010 Sep; 88(3):405-7. PubMed ID: 20668447 [TBL] [Abstract][Full Text] [Related]
15. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples. Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303 [TBL] [Abstract][Full Text] [Related]
16. BDDCS class prediction for new molecular entities. Broccatelli F; Cruciani G; Benet LZ; Oprea TI Mol Pharm; 2012 Mar; 9(3):570-80. PubMed ID: 22224483 [TBL] [Abstract][Full Text] [Related]
17. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number. Pham-The H; Garrigues T; Bermejo M; González-Álvarez I; Monteagudo MC; Cabrera-Pérez MÁ Mol Pharm; 2013 Jun; 10(6):2445-61. PubMed ID: 23675957 [TBL] [Abstract][Full Text] [Related]
18. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413-420, 1995--backstory of BCS. Shah VP; Amidon GL AAPS J; 2014 Sep; 16(5):894-8. PubMed ID: 24961917 [TBL] [Abstract][Full Text] [Related]
19. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. Dahan A; Miller JM; Amidon GL AAPS J; 2009 Dec; 11(4):740-6. PubMed ID: 19876745 [TBL] [Abstract][Full Text] [Related]
20. A non-binary biopharmaceutical classification of drugs: the ABΓ system. Macheras P; Karalis V Int J Pharm; 2014 Apr; 464(1-2):85-90. PubMed ID: 24456673 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]